Let’s do something amazing together! The Associate Director, National Accounts will play a critical role in enabling patient access to Arrowhead’s first commercial asset, Redemplo (plozasiran, siRNA targeting APOC3), as well as an expanding pipeline of innovative therapies across multiple therapeutic areas. This product has demonstrated compelling clinical data to date and received approval in November 2025 for the treatment of Familial Chylomicronemia Syndrome (FCS). Redemplo (plozasiran) remains in late-stage development for the treatment of Severe Hypertriglyceridemia (SHTG), with approval anticipated in Q2 2027.
This individual will own a dedicated portfolio of payer and PBM accounts while also serving as a strategic, customer-facing partner to the National Account Directors (NADs) on Arrowhead’s broader national accounts, and as a centralized source of truth for payer contracts, formulary coverage, payer policies, and utilization management criteria across Arrowhead’s U.S. Market Access footprint. The role will translate formulary, claims, and specialty pharmacy data into payer strategy and field-facing insights, partnering closely with the NADs, Trade, Distribution, and Patient Services leadership to strengthen Arrowhead’s payer intelligence capabilities and represent that intelligence directly to internal leadership and external payer and PBM audiences. This is an individual contributor role with no direct reports, requiring high executive presence, polished presentation skills, and the confidence to stand alongside the NADs in front of senior payer and PBM stakeholders.
This is a field-based or remote role that requires periodic travel to Arrowhead’s Corporate Headquarters in Pasadena, CA, and to payer and PBM industry conferences, as business needs dictate